Trial Profile

Efficacy and safety study of dapagliflozin in type 1 diabetes mellitus patients

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 08 Aug 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dapagliflozin (Primary)
Indications Type 1 diabetes mellitus
Focus Therapeutic Use
Acronyms RISING-STAR

Most Recent Events

08 Aug 2021 New trial record
29 Jun 2021 Primary endpoint (the frequency of hypoglycemia by instructing basal insulin dose reduction) has not been met, according to Results presented at the 81st Annual Scientific Sessions of the American Diabetes Association
29 Jun 2021 Results presented at the 81st Annual Scientific Sessions of the American Diabetes Association

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com